Close Menu

NEW YORK (GenomeWeb) – By systematically introducing mutations into the BRCA1 gene, researchers have sought to better classify which variants are likely to be pathogenic or benign.

BRCA1 is one of the best-studied genes, but the impact of its numerous variants on breast and ovarian cancer risk remains unclear. Such variants of uncertain significance (VUS) limit the clinical utility of a patient's data, said the authors of the new study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.